The First Male Birth Control Pill Is Finally Here | Akash Bakshi - CEO, YourChoice Therapeutics

For decades, male birth control has remained one of medicine’s most elusive goals. Now, a new non-hormonal pill is entering human trials—and could finally change the balance of reproductive responsibility

Akash Bakshi is CEO and Co-Founder of YourChoice Therapeutics ( https://www.yourchoicetx.com/ ), a company working to develop the first hormone-free birth control pill for men.

Akash’s work sits at the intersection of biotechnology innovation, reproductive health, and social change. His team is advancing YCT-529, a first-in-class non-hormonal contraceptive currently in human clinical trials, designed to safely and reversibly suppress sperm production by targeting retinoic acid signaling.

Before founding YourChoice, Akash held leadership roles across biotech and drug development, including serving as CEO of ANA Therapeutics, where he rapidly advanced a COVID-19 therapeutic into clinical trials and led the company through acquisition, as well as COO of NeuroBo Pharmaceuticals.

Earlier in his career, Akash worked at University of California, Berkeley helping bridge early-stage science and commercialization—experience that clearly shaped his approach to translating breakthrough academic research into real-world therapies.

At a time when contraceptive responsibility has largely fallen on women—and amid growing debates around reproductive rights—Akash and his team are trying to fundamentally reshape the landscape.

#MaleBirthControl #BirthControlPillForMen #NonHormonalContraception #YCT529 #BiotechBreakthrough #FutureOfMedicine #ReproductiveHealth #MensHealth #WomensHealth #FertilityScience #PharmaInnovation #ClinicalTrials #BiotechStartups #HealthcareInnovation #EndUnintendedPregnancy #SciencePodcast #LongevityAndHealth #DrugDevelopment #MedicalBreakthrough #ContraceptionRevolution #FutureOfHealthcare #RARalpha #YourChoiceTherapeutics #BiotechCEO #HealthTech #PostRoeWorld